SAN DIEGO--(BUSINESS WIRE)--Today, DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced its non-invasive platform technology is highlighted in Nature’s November issue of BioPharma Dealmakers (http://bit.ly/1kSNst7). DermTech is the first to offer gene expression tests to the clinical dermatologist that can be used as an aid in diagnosis with specimens collected using an adhesive patch rather than scalpel. DermTech’s platform technology can be used as a stand alone diagnostic or a diagnostic aid for difficult to identify skin conditions such as skin cancers. DermTech’s innovative platform can also be used to support clinical drug development both to stratify patients and to monitor clinical response. DermTech has current collaborations with Biogen and Astra Zeneca/ MedImmune.
Help employers find you! Check out all the jobs and post your resume.
